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doi:10.1016/j.jss.2006.10.045Background. Several biological markers have been
related to prognosis in mammary ductal carcinoma.
The aim of the study was to determine biological
markers that could predict local recurrence following
treatment for all stages of primary operable ductal
carcinoma of the breast.
Materials and methods. A consecutive series of pa-
tients treated for pure ductal carcinoma in situ (DCIS,
n  110) and invasive ductal carcinoma (IDC, n  243)
was studied. Twenty-three patients with DCIS were
excluded because of lack of original paraffin embed-
ded tissue. All patients had been treated between July
1996 and December 2001. Median follow-up was 49.8
mo. From the original paraffin embedded tumors, tis-
sue microarrays (TMAs) were constructed. On these
TMAs, immunohistochemistry was performed for
estrogen-receptor (ER), progesterone-receptor (PR),
Her2/neu, p53, and cyclin D1. Main outcome was the
event of LR. All analyses were stratified for diagnosis
(DCIS or IDC) and pathological grade.
Results. In univariate analyses, Her2/neu overex-
pression (hazard ratio [HR] 3.1, 95% confidence inter-
val [CI] 1.1–8.7, P  0.032) and p53 overexpression (HR
3.5, 95% CI 1.3–9.3, P  0.014) were associated with LR
in patients treated for both DCIS and IDC. In multi-
variate analysis, p53 overexpression (HR 3.0, 95% CI
1.1–8.2, P 0.036 and HR 4.4, 95% CI 1.5–12.9, P 0.008)
and adjuvant radiotherapy (HR 0.2, 95% CI 0.1–0.8, P
0.026) were independent common predictors of LR in
patients who had received treatment for both DCIS
and IDC.
1 To whom correspondence and reprint requests should be ad-
dressed at Department of Surgical Oncology, University Medical
Center Groningen, University of Groningen, Hanzeplein 1, P.O. Box
30001, 9700 RB Groningen, The Netherlands. E-mail: m.a.j.de.roos
@chir.umcg.nl.
109Conclusions. p53 overexpression is a common pre-
dictor of LR following treatment for all stages of pri-
mary operable ductal carcinoma of the breast. This
marker may help in planning optimal treatment and
follow-up. © 2007 Elsevier Inc. All rights reserved.
Key Words: breast neoplasms; local neoplasm recur-
rence; ductal carcinoma in situ; immunohistochemis-
try; biological markers.
INTRODUCTION
Local recurrence (LR) is an adverse event in the
treatment of ductal carcinoma of the breast and, as a
first event in follow-up, influences prognosis signifi-
cantly after treatment for all primary operable stages
of this disease. In ductal carcinoma in situ (DCIS) the
10-y disease specific survival decreases from almost a
100 to 92% in the case of LR [1, 2]. In primary operable
invasive ductal carcinoma (IDC), the 5- and 10-y over-
all survival rate of patients with LR after breast con-
serving therapy for early breast cancer is 81% [3] and
39% [4], respectively, and the 5-y overall survival rate
of patients with LR following mastectomy is 42% [5].
Established biological markers for prognosis that
have been studied in both ductal carcinoma in situ
(DCIS) and invasive ductal carcinoma (IDC) are estro-
gen receptor (ER), progesterone receptor (PR), Her2/
neu, p53, and cyclin D1 [6, 7]. There appear to be many
parallels between DCIS and IDC with regard to the
expression of these markers and their prognostic sig-
nificance.
Since the incidence of LR reduces survival after
treatment for all stages of primary operable ductal
carcinoma of the breast, the aim of this study was to
identify biological markers that could predict LR fol-
lowing treatment for all stages of this disease. There-
0022-4804/07 $32.00
© 2007 Elsevier Inc. All rights reserved.
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a consecutive series of tumors from patients with DCIS
and a consecutive series of tumors from patients with
IDC followed by immunohistochemistry for the above
mentioned biological markers. These markers were
tested for their predictive power of LR. The analyses




One hundred ten consecutive patients treated for DCIS and 243
consecutive patients treated for a primary operable IDC were iden-
tified between July 1996 and December 2001. Patients and tumors
were selected on the availability of the original pathological slides
and sufficient paraffin embedded tissue. Eighty-seven DCIS tumors
and all IDC tumors (n 243) were included in the study. Patient and
tumor characteristics and data on follow-up were obtained retrospec-
tively from hospital records and are summarized in Table 1. Patho-
logical grade for DCIS was classified according to the European
Pathologists Working Group (EPWG) [8] and pathological grade for
IDC was scored according to Elston and Ellis [9]. The median
follow-up was 49.8 mo. Follow-up was performed according to the
regional follow-up guidelines (http://www.ikcnet.nl/page.php?id97).
LR was classified as ipsilateral recurrence near the site of the orig-
inal tumor in the breast in the case of breast conserving therapy and
near the scar tissue on the thoracic wall in the case of a mastectomy.
Axillary recurrence was not regarded as LR. During follow-up, 18
patients developed LR after a median follow-up of 27.8 mo. Thirty-
four patients developed distant metastasis after a median follow-up
of 29.7 mo.
Tissue Microarray Construction
Slides from all blocks were evaluated for representative areas
with DCIS or IDC and TMAs were prepared as described earlier [10].
In brief, the most representative area of tumor was marked on the
original hematoxylin and eosin (H&E) stained section. With this
marked section as an orientation, three 0.6 mm punches were taken
from the selected area in the donor blocks and mounted in a recipient
block containing approximately 110 biopsies, using a manual tissue
microarray device (Beecher Instruments, Silver Springs, MD).
Immunohistochemistry
Immunohistochemistry for ER, PR, Her2/neu, cyclin D1, and p53
was performed on these sections. The antibodies and antigen re-
trieval methods are summarized in Table 2. The immunostaining
protocol was as follows: sections were deparaffinized in pure xylene,
rehydrated in decreasing concentrations of ethanol, and washed in
distilled water. Antigen retrieval was performed. The endogenous
peroxidase reaction was blocked by incubating in 3% perhydrol for 30
min. The primary antibody diluted in PBS containing 1% bovine
serum albumin was incubated for 1 h, after which the secondary
(1:100 diluted in PBS containing 1% BSA and 1% AB-serum) and
tertiary (1:100 diluted in PBS containing 1% BSA and 1% AB-serum)
were incubated for 30 min each. Visualization was performed using
the diaminobenzidine tetrahydrochloride/peroxidase reaction. Coun-
terstaining was performed using hematoxylin. Sections were dehy-
drated using rising concentrations of alcohol and were mounted.
Evaluation of Immunohistochemistry
Scoring of the stainings was performed by two well-trained resi-
dents (BvdV and MdR). The scoring was randomly verified by anexperienced pathologist (JW). ER, PR, p53, and cyclin D1 were
graded based on the percentage of tumor cells showing positive
nuclear staining. ER, PR, and cyclin D1 were considered positive if
nuclear staining was present in 10% of the cells, and p53 was
considered positive (overexpression) in case of a substantial percent-
age of positively stained nuclei (30%). Her2/neu expression was
graded as recommended by the manufacturer’s scoring guidelines; 0:
no staining at all or membrane staining in 10% of the tumor cells;
1: a faint/barely perceptible partial membrane staining in 10% of
the tumor cells; 2: weak to moderate complete membrane staining
in 10% of the tumor cells; 3: strong complete membrane staining
in 10%. Her2/neu was considered positive if the score was 3.
Statistical Analysis
Univariate logistic regression analyses, investigating the effect of
biological markers on local recurrence, were performed using Cox
regression models. All analyses were adjusted for diagnosis and
pathological grade to obtain diagnosis and grade independent pre-
dictors. Variables with a P value 0.10 were included in a multivar-
TABLE 1
Clinico-Pathological and Biological Parameters of
the Study Population
Clinico-pathological
characteristics DCIS (n  87) IDC (n  243)
Age (median) 57.7 (36.8–77.5) 57.9 (27–89)
Screening detected 52 70
Palpable lesion 12 198
Surgery






2 cm 37 135














Hormonal therapy — 87
Follow-up
No problems 79 198
Local recurrence 7 11
Axillary recurrence — 1
Metastasis 1 33
DCIS  ductal carcinoma in situ; IDC  invasive ductal carci-
noma.
* Pathological grade for DCIS was classified according to the
European Pathologists Working Group [8] classification and
pathological grade for IDC was scored according to Elston and
Ellis [9].iate logistic regression analysis that was also performed with a Cox
111DE ROOS ET AL.: BIOLOGICAL MARKERS FOR LOCAL RECURRENCEregression model. The selection of variables in a stepwise manner
identified the statistically significant clinico-pathological and biolog-
ical parameters. Finally, clinico-pathological variables known to be
related to prognosis were entered in a multivariate Cox regression
model evaluating the predictive power of p53. P values of0.05 were
considered significant. All calculations were performed with SPSS
12.01 (SPSS Inc., Chicago, IL).
RESULTS
From the 87 DCIS cases, representative tissue cores
were obtained in 80 cases (92%) and acceptable immu-
nohistochemistry (at least one of the three cores was
stained sufficiently) was achieved in 69 (79%) cases for
p53-, 70 (80%) cases for cyclin D1- and PR-staining, 73
cases (84%) for ER-staining, and 80 cases (92%) for
Her2/neu staining. Out of the 243 IDC cases, the tissue
cores of 237 cases (98%) were adequately represented
in the TMA. Immunohistochemistry could be evaluated
in all cases (100%, n  237) for p53 and D1, in 235
cases (99%) for Her2/neu, in 232 cases (98%) for ER,
and in 230 cases (97%) for PR.
The relation of the biological markers with local re-
currence in univariate analysis is outlined in Table 3.
Her2/neu overexpression (hazard ratio [HR] 3.1, 95%
confidence interval [CI] 1.1–8.7, P  0.032) and p53
overexpression (HR 3.5, 95% CI 1.3–9.3, P  0.014)
were associated with LR in patients treated for both
DCIS and IDC (stratification for diagnosis).
In multivariate analysis (including Her2/neu- and
p53 overexpression), p53 positive immunoreactivity
(HR 3.0, 95% CI 1.1–8.2, P  0.036) was an indepen-
dent common predictor of LR in patients that had
received treatment for both DCIS and IDC (Table 4).
To evaluate the power of prediction of Her2neu and
p53 in relation to clinico-pathological parameters that
are known for their association with prognosis Her2/
neu overexpression and p53 overexpression were eval-
uated in a multivariate analysis model including these
TAB
Antigen Retrieval M
Antibody Clone Supplier Dilution Anti
ER 6F11 Ventana * Tris/HC
30’ 9
PR 1A6 Ventana * Tris/HC
30’ 9
Her2/Neu CB11 Ventana * Tris/HC
30’ 9
p53 BP-53-12-1 Biogenix 1:800 Tris/HC
30’ 9
Cyclin D1 SP4 Neomarkers 1:50 Tris/HC
30’ 9
ER  estrogen receptor; PR  progesteron receptor; *  predilut
antirabbit biotin.clinico-pathological parameters. In this analysis adju-vant radiotherapy (HR 0.2, 95% CI 0.1–0.8, P  0.026)
and p53 overexpression (HR 4.4, 95% CI 1.5–12.9, P 
0.008) were both independent predictors of LR irre-
spective of DCIS or IDC (Table 5).
DISCUSSION
In this study, established biological markers were
evaluated for their predictive capacities for LR follow-










RAMBIO Dako SARBIO Dako
.1M (pH 9.5)
microwave
RAMBIO Dako SARBIO Dako
.1M (pH 9.5)
microwave
RAMBIO Dako SARBIO Dako
.1M (pH 9.5)
microwave
RAMBIO Dako SARBIO Dako
.1M (pH 9.5)
microwave
RAMBIO Dako SARBIO Dako
y supplier; RAMBIO  rabbit antimouse biotin; SARBIO  swine
TABLE 3
Biological Markers and Local Recurrence, Univari-
ate Analysis, Adjusted for DCIS or IDC and Patholog-
ical Grade (Cox Regression)
Biological marker Study population HR 95% CI P value
Her2/neu









Negative 122 1.1 0.4-3.0 0.895
n  303
p53





Negative 98 1.5 0.6-4.1 0.402
n  316
HR  hazard ratio, adjusted for pathological diagnosis (DCIS or













ed breceptor; PR  progesterone receptor.
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be an independent predictor of LR in patients irrespec-
tive of treatment for in situ or node-negative or
-positive invasive ductal carcinoma (HR 4.4, 95% CI
1.5–12.9, P  0.008). Adjuvant radiotherapy (HR 0.2,
95% CI 0.1–0.8, P  0.026) was another independent
predictor of LR. In univariate logistic regression anal-
ysis Her2/neu overexpression was also related with LR
(HR 3.1, 95% CI 1.1–8.7, P  0.032).
The p53 gene is a tumor suppressor gene located on
the short arm of chromosome 17 at the position
17p13.1. It encodes a 53kD nuclear phosphoprotein,
p53, which maintains genomic integrity by inducing
cell cycle arrest or apoptosis in case of acquired DNA
damage [11]. Mutations in one allele of the p53 gene
can result in inactivation or alteration of its function.
Such mutations occur in many human cancers includ-
ing in approximately 20% of the breast carcinomas
[12]. Normal p53 protein is practically undetectable by
immunohistochemistry because of the short half-life of
the protein and the low amount of p53 protein present
in the cell. Overexpression of p53 detected by immuno-
histochemistry indicates mutation of the p53 gene,
which leads to a stabilized form and nonfunctional
form of p53 [12].
Most studies on p53 overexpression and prognosis in
patients with resectable node-positive and node-
negative breast cancer have observed a shortened
relapse-free and/or overall survival in case of tumors
with a positive immunoreactivity for p53 [13, 14].
There are, however, other reports that have not found
such an effect on prognosis [15, 16]. Discrepant find-
ings may be explained by the diversity in the different
antibodies for p53 and scoring methods for p53 immu-
noreactivity.
Fewer studies have investigated the relation of p53
protein expression with LR. After evaluation of sev-
eral clinico-pathological factors and biomarkers in a
case-control study of 66 patients with LR following
breast conserving therapy, p53 was found to be an
TABLE 4
Biological Predictors of Local Recurrence, Multivar-
iate Analysis, Adjusted for DCIS or IDC and Patholog-
ical Grade (Cox Regression)
Biological marker HR 95% CI P value
Her2/neu over expression
Positive 2.3 0.8-6.5 0.132
Negative 1
p53
Positive 3.0 1.1-8.2 0.036
Negative 1
Note. Regression analysis. HR adjusted for pathological diagnosis
(DCIS or IDC) and grade.independent predictor of LR [17]. Similar results havebeen obtained in the study by Turner et al. [18] In
DCIS, there are not many studies that describe the
relation between p53 immunoreactivity and LR. Two
groups of investigators, however, have shown that p53
positive expression is also associated with LR in DCIS
[19, 20].
In this present series, the majority of patients was
treated with mastectomy (DCIS 55.2% and IDC
59.7%). Chest wall recurrence is not very common and
was not present in patients treated for DCIS. In pa-
tients treated for IDC, however, chest wall recurrence
was present in eight cases. Zellars et al. [21] have
demonstrated the prognostic value of p53 overexpres-
sion for local failure in 1530 mastectomy treated pa-
tients.
The exact relation of mutant p53 with LR remains
unclear, however. The short median follow-up in which
local recurrences developed (27.8 mo) in this study
suggests a clonogenic origin of these recurrences. The
fact that p53 overexpression is a predictor of LR in
TABLE 5
Multivariate Analysis Including Clinico-Pathological
Parameters Known to be Related with Prognosis Inves-
tigating the Relation with Local Recurrence in Order to
Test the Predictive Power of p53 Expression
Characteristics HR 95% CI P value
Surgical procedure
Lumpectomy 3.1 0.7-12.4 0.092
Mastectomy 1
Margins
Positive 3.2 0.7-13.5 0.118
Negative 1
Pathological size
2 cm 1.1 0.4-3.0 0.900
2 cm 1
Pathological grade*
1 0.9 0.2-5.1 0.979
2 0.4 0.1-1.5 0.181
3 1
Axillary status
Positive 2.6 0.4-18.6 0.351
Negative 1
Adjuvant radiotherapy
Yes 0.2 0.1-0.8 0.026
No 1
Adjuvant chemotherapy
Yes 0.3 0.1-2.1 0.231
No 1
Her-2/neu overexpression
Positive 2.1 0.7-6.4 0.195
Negative 1
p53
Positive 4.4 1.5-12.9 0.008
Negative 1
Note. Regression analysis. HR adjusted for pathological diagnosis
(DCIS or IDC). Pathologists Working Group [8] classification and
pathological grade for IDC was scored according to Elston and Ellis [9].
* Pathological grade for DCIS was classified according to the
European.
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noma suggests the presence of a biologically more ag-
gressive subgroup throughout all stages of breast can-
cer progression. An explanation for the relation of p53
overexpressing tumors with LR may be a more ag-
gressive biological profile and behavior, but could
also be a consequence of p53-related treatment re-
sistance [22]. In this retrospective study with a con-
secutive series of patients, all being treated accord-
ing to existing guidelines, including adjuvant
endocrine- or chemotherapy and radiotherapy, it is
very difficult to entirely separate prognostic and pre-
dictive characteristics. Adjuvant radiotherapy was
an independent predictor of LR (HR 0.2, 95% CI
0.1– 0.8, P  0.026). However, there was no relation
between LR and adjuvant chemotherapy (HR 0.4,
95% CI 0.1–2.0; P  0.461).
The identification of a predictive marker for LR
throughout the progression of ductal carcinoma may
help in guiding the optimal treatment for every stage of
this disease. p53 expression may particularly influence
choice of therapy in patients with pure DCIS because
mastectomy results in a survival rate of almost 100%.
This marker may also be used for therapeutic consid-
erations in more progressed stages of ductal carci-
noma. In a study by Mieog et al. [23], p53 overex-
pression was an independent predictor of clinical
tumor response after anthracycline based neo-
adjuvant chemotherapy for patients with operable
breast cancer. In contrast with the findings of
Elledge and Allred [22], Silvestrini et al. demon-
strated that radiation therapy seems to prevent LR
in patients with tumors that express elevated levels
of p53 [24].
We also found a relation of Her2/neu overexpression
with LR (HR 3.1, 95% CI 1.1–8.7, P  0.032). Other
studies concerning Her2/neu overexpression and prog-
nosis in invasive cancer have indicated a relation with
chest wall recurrence after mastectomy [25] and with
disease recurrence following BCT [26]. In the last study
[26], a relation with LR could not be demonstrated. In
DCIS, Her2/neu overexpression is associated with high
pathological grade [27] and with LR [28].
Cyclin D1 did not show any effect on LR in our series
(negative staining; HR 1.5, 95% CI 0.6–4.1, P 0.402).
Turner et al. have investigated the influence of cyclin
D1 protein expression on breast cancer recurrence in a
case-matched study in 49 patients and found that low
levels of immunohistochemically detected cyclin D1
protein correlated with LR [29]. Also, in DCIS, low
levels of cyclin D1 protein expression were associated
with local recurrence [30]. As has been suggested be-
fore, these different findings from our study may be
explained by different antibodies for cyclin D1 and
methods of detection.In conclusion, p53 overexpression is an independentpredictor of LR in patients treated throughout all
stages of primary operable ductal carcinoma of the
breast including in situ ductal carcinoma. This marker
may help in planning optimal treatment and follow-up.
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